Q2 revenue falls 25%, but first-half loss narrows sharply

Revenue DeclinePat NegativeEbitda Margin ExpansionNegative Operating CashflowResults View source PDF Explain this filing

ASTEC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹675.40

prior close

₹670.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%-1.8% vs market

Pesticides & Agrochemicals peers, median of 26sector-0.2%-1.8% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.8 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.4

15m

-0.6

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0-0.2-1.8-0.2-1.8

Next day

-2.0-0.5-1.4-1.1-0.9

-0.9+0.5-1.5-1.6+0.7

-1.1-0.2-0.8-2.9+1.8

-5.0-1.9-3.1-4.7-0.3

-5.8-1.5-4.3-4.6-1.2

-8.3-2.2-6.1-7.4-0.9

15d

+22.2-3.6+25.8-8.8+31.0

+20.8-3.5+24.4-6.8+27.6

+4.2-7.0+11.3-12.1+16.3

-15.3-11.1-4.2-17.0+1.7

UpDownMarket · Nifty Microcap 250Sector · Pesticides & Agrochemicals peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Astec LifeSciences reported unaudited second-quarter revenue of Rs 73.72 crore, down 25.2% from Rs 98.55 crore. First-half revenue was Rs 164.80 crore versus Rs 167.92 crore. Standalone first-half loss narrowed to Rs 57.51 crore from Rs 78.31 crore, while operating margin improved to minus 10.72% from minus 39.29%. Operating cash flow stayed negative at Rs 12.77 crore. The auditor gave an unmodified opinion.

Likely market impact

Losses narrowed and debt ratio improved after the rights issue, but falling revenue and cash burn remain concerns; the stock response may be mixed.